R. Siegel, D. Naishadham, and A. Jemal, Cancer statistics, CA Cancer J Clin, vol.63, issue.1, pp.61347-61347, 2012.

B. Scaggiante, M. Kazemi, G. Pozzato, B. Dapas, R. Farra et al., Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials, World J Gastroenterol, vol.20, issue.5, pp.1268-1288, 2014.

P. Bertuccio, F. Turati, G. Carioli, T. Rodriguez, L. Vecchia et al., Global trends and predictions in hepatocellular carcinoma mortality

, J Hepatol, vol.67, issue.2, pp.302-309, 2017.

N. Tsuchiya, Y. Sawada, I. Endo, K. Saito, Y. Uemura et al., Biomarkers for the early diagnosis of hepatocellular carcinoma, World J Gastroenterol, vol.21, issue.37, p.10573, 2015.

T. Duarte-salles, S. Misra, M. Stepien, and A. Plymoth,

D. Muller, K. Overvad, A. Olsen, A. Tjønneland, L. Baglietto et al., Circulating osteopontin and prediction of hepatocellular carcinoma development in a large European population, Cancer Prev Res (Phila), vol.9, issue.9, pp.758-765, 2016.

J. Bruix, G. J. Gores, and V. Mazzaferro, Hepatocellular carcinoma: clinical frontiers and perspectives, Gut, vol.63, issue.5, pp.844-855, 2014.

S. Geneva, , 2014.

L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-tieulent et al., Global cancer statistics, CA Cancer J Clin, vol.65, issue.2, pp.87-108, 2012.

J. Rowe, Y. Ghouri, and I. Mian, Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis

, Ozakyol A. Global epidemiology of hepatocellular carcinoma (HCC epidemiology), J Gastrointest Cancer, vol.16, issue.1, p.1, 2017.

V. V. Breder, V. Y. Kosyrev, and N. E. Kudashkin, , vol.48, pp.238-240

K. K. Laktionov, M. G. Chávez-lópez, V. Zúñiga-garcía, J. I. Pérez-carreón, A. Avalos-fuentes et al., Hepatocellular carcinoma as a social and medical problem in the Russian Federation, Medicinskij sovet, vol.10, pp.139-148, 2016.

, Niger J Clin Pract, vol.20, issue.10, pp.1267-1272, 2017.

V. T. Kiriienko, I. A. Zaitsev, V. V. Hrushkevych, and V. Potii, Screening and early diagnosis of hepatocellular carcinoma

, Aktual'naa infektologia, vol.6, issue.2, pp.70-76, 2018.

F. Durand, C. Antoine, and O. Soubrane, Liver hepatocellular carcinoma (review), Oncol Rep, vol.37, issue.3, pp.1291-1300, 2017.

D. Xu, C. Su, L. Sun, Y. Gao, and Y. Li, Performance of serum glypican 3 in diagnosis of hepatocellular carcinoma: a meta-analysis, Ann Hepatol, vol.18, issue.1, pp.58-67, 2018.

J. A. Marrero, P. R. Romano, O. Nikolaeva, L. Steel, A. Mehta et al., GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma, J Hepatol, 2005.

J. S. Hu, D. W. Wu, S. Liang, and X. Miao, GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population, Med Oncol, vol.43, issue.6, pp.339-345, 2010.

C. Jiao, L. Cui, J. Piao, Y. Qi, and Z. Yu, Clinical significance and expression of serum Golgi protein 73 in primary hepatocellular carcinoma, J Cancer Res Ther, vol.14, issue.6, pp.1239-1244, 2018.

G. Giannelli, F. Marinosci, P. Trerotoli, A. Volpe, M. Quaranta et al., SCCA antigen combined with alpha-fetoprotein as serologic markers of HCC, Int J Cancer, vol.117, issue.3, pp.506-509, 2005.

F. Marinosci, L. Lupo, G. Nkontchou, P. Dentico, C. D. Antonaci-s-;-witjes et al., Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients, Clin Chim Acta, vol.383, issue.1-2, pp.59-64, 2007.

C. Pozzan, R. Cardin, M. Piciocchi, and N. Cazzagon,

G. Maddalo, V. Vanin, A. Giacomin, P. Pontisso, U. Cillo et al., Diagnostic and prognostic role of SCCA-IgM serum levels in hepatocellular carcinoma (HCC), J Gastroenterol Hepatol, vol.29, issue.8, pp.1637-1644, 2014.

C. H. Liu, A. Gil-gómez, J. Ampuero, L. Romero-gómez-m-;-beneduce, F. Castaldi et al., Squamouse cell carcinoma antigenimmunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma, Liver Int, vol.38, issue.10, pp.2558-2565, 2005.

J. Kim, S. S. Ki, S. D. Lee, C. J. Han, Y. C. Kim et al., Elevated plasma osteopontin levels in patients with hepatocellular carcinoma, Am J Gastroenterol, vol.101, issue.9, pp.2051-2059, 2006.

S. Shang, A. Plymoth, S. Ge, Z. Feng, H. R. Rosen et al., Identification of osteopontin as a novel marker for early hepatocellular carcinoma, Hepatology, vol.55, issue.2, pp.483-490, 2012.

H. G. Wan, H. Xu, Y. M. Gu, H. Wang, W. Xu et al., Comparison osteopontin vs AFP for the diagnosis of HCC: a meta-analysis, Clin Res Hepatol Gastroenterol, vol.38, issue.6, pp.706-714, 2014.

T. Ge, Q. Shen, N. Wang, Y. Zhang, Z. Ge et al., Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma, Med Oncol, vol.32, issue.3, p.59, 2015.

N. Y. Ji, M. Y. Park, Y. H. Kang, C. I. Lee, D. G. Kim et al., Evaluation of annexin II as a potential serum marker for hepatocellular carcinoma using a developed sandwich ELISA method, Int J Mol Med, vol.24, issue.6, pp.765-771, 2009.

Y. Sun, G. Gao, J. Cai, Y. Wang, X. Qu et al.,

Y. Zhang, K. Lin, S. Ma, X. Yang, X. Qian et al., Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma, Carcinogenesis, vol.34, issue.3, pp.595-604, 2013.

I. F. Montasser, S. M. Abdelhakam, E. El-hadidy, R. Yousry, and A. K. El-dorry, Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients, World J Hepatol, vol.9, issue.9, pp.469-476, 2017.

H. Toyoda, T. Kumada, T. Tada, Y. Kaneoka, and A. Maeda,

F. Kanke and S. Satomura, Clinical utility of highly sensitive lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20 ng/ml, Cancer Sci, vol.102, issue.5, pp.1025-1031, 2011.

K. Oda, A. Ido, T. Tamai, M. Matsushita, K. Kumagai et al., Highly sensitive lens culinaris agglutininreactive ?-fetoprotein is useful for early detection of hepatocellular carcinoma in patients with chronic liver disease, Oncol Rep, vol.26, issue.5, pp.1227-1233, 2011.

E. K. Tung, I. O. Ng, Q. Shen, J. Fan, X. R. Yang et al., Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study, Future Oncol, vol.8, issue.12, pp.70233-70237, 2012.

J. Zhang, Y. Zhao, and Q. Yang, Sensitivity and specificity of dickkopf-1 protein in serum for diagnosing hepatocellular carcinoma: a meta-analysis, Int J Biol Markers, vol.29, issue.4, pp.403-410, 2014.

S. Van-hees, P. Michielsen, Q. F. Vanwolleghem-t-;-qin, J. Weng, G. X. Xu et al., Circulating predictive and diagnostic biomarkers for hepatitis B virusassociated hepatocellular carcinoma, World J Gastroenterol, vol.22, issue.37, pp.8271-8282, 2016.

P. Reichl, M. Fang, P. Starlinger, K. Staufer, R. Nenutil et al., Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma, Asian Pac J Trop Med, vol.10, issue.4, pp.409-413, 2017.

, Int J Cancer, vol.137, issue.2, pp.385-394, 2015.

M. Dengler, K. Staufer, H. Huber, R. Stauber, H. Bantel et al., Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis, Oncotarget, vol.8, issue.28, pp.46234-46248, 2017.

J. B. Zhang, C. A. Loffredo, M. Forgues, H. Huang, X. J. Xing et al., Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma, Clin Cancer Res, vol.19, issue.14, pp.3944-3954, 2013.

K. Y. Shaheen, A. I. Abdel-mageed, E. Safwat, A. M. Albreedy, R. Vongsuvanh et al., Midkine increases diagnostic yield in AFP negative and NASH-related hepatocellular carcinoma, Int J Hepatol, vol.11, issue.5, p.155800, 2015.

T. Zheng, M. Chen, S. Han, L. Zhang, Y. Bai et al., Plasma minichromosome maintenance complex component 6 is a novel biomarker for hepatocellular carcinoma patients, Hepatol Res, vol.44, issue.13, pp.1347-1356, 2014.

J. Li, Z. J. Cheng, Y. Liu, Z. L. Yan, K. Wang et al., Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma, Oncotarget, vol.6, issue.11, pp.9551-9563, 2015.

A. Chounta, C. Ellinas, V. Tzanetakou, F. Pliarhopoulou, V. Mplani et al., Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma, Liver Int, vol.35, issue.2, pp.601-607, 2015.

S. Gupta, S. Bent, and J. Kohlwes, Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis, Ann Intern Med, vol.139, issue.1, pp.46-50, 2003.

J. D. Yang, J. Dai, A. G. Singal, P. Gopal, B. D. Addissie et al., Improved performance of serum alpha-fetoprotein for hepatocellular carcinoma diagnosis in HCV cirrhosis with normal alanine transaminase, Cancer Epidemiol Biomarkers Prev, vol.26, issue.7, pp.1085-1092, 2017.

C. Sauzay, A. Petit, A. M. Bourgeois, J. C. Barbare, B. Chauffert et al., Alpha-foetoprotein (AFP): a multi-purpose marker in hepatocellular carcinoma

, Clin Chim Acta, vol.463, pp.39-44, 2016.

C. W. Yen, Y. H. Kuo, J. H. Wang, K. C. Chang, K. M. Kee et al., Did AFP-L3 save ultrasonography in community screening?, Kaohsiung J Med Sci, vol.34, issue.10, pp.583-587, 2018.

B. J. Mcmahon, L. Bulkow, A. Harpster, M. Snowball, A. Lanier et al., Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study, Hepatology, vol.32, issue.4, pp.842-846, 2000.

R. K. Sterling, L. Jeffers, F. Gordon, A. P. Venook, K. R. Reddy et al.,

M. Sherman, A. Uni?, L. Derek, M. Duvnjak, L. Patrlj et al., Utility of lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma, Clin Gastroenterol Hepatol, vol.7, issue.1, pp.355-362, 2009.

P. M. Hemken, L. J. Sokoll, X. Yang, J. Dai, D. Elliott et al., Validation of a novel model for the early detection of hepatocellular carcinoma, Clin Proteomics, vol.16, issue.2, 2019.

N. Yamashiki, Y. Sugawara, S. Tamura, J. Kaneko, H. Yoshida et al., Diagnostic accuracy of alpha-fetoprotein and des-gamma-carboxy prothrombin in screening for hepatocellular carcinoma in liver transplant candidates, Z Gastroenterol, vol.41, issue.12, pp.1296-1305, 2011.

J. Wu, Z. Xiang, L. Bai, L. He, L. Tan et al., Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA, Cancer Biomark, vol.23, issue.2, pp.235-242, 2018.

R. Yu, Z. Tan, X. Xiang, Y. Dan, Z. Deng-g-;-shuang et al., Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data, BMC Cancer, vol.17, issue.1, p.608, 2017.

J. Chen, F. Duan, and S. Li, Alpha-L-fucosidase serves as a prognostic indicator for intrahepatic cholangiocarcinoma and inhibits its invasion capacity, Biomed Res Int, p.8182575, 2018.

L. Vivancos, J. Segura, R. M. Oliva, G. Vives, L. Pascual et al., Value of the serum measurement of alpha-L-fucosidase in the diagnosis of hepatocarcinoma, Med Clin (Barc), vol.93, issue.7, pp.241-243, 1989.

H. Ishizuka, T. Nakayama, S. Matsuoka, I. Gotoh, M. Ogawa et al., Prediction of the development of hepato-cellular-carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-L-fucosidase activity, Intern Med, vol.38, issue.12, pp.927-931, 1999.

M. Sakamoto, R. Tsuchiya, H. Kato, and K. Furuta, Prediction of invasive activities in hepatocellular carcinomas with special reference to alpha-fetoprotein and des-gammacarboxyprothrombin, Jpn J Clin Oncol, vol.33, issue.10, pp.522-526, 2003.

M. A. Abdelrazek, A. A. Attallah, A. M. Saeed, and K. Farid, GPC-HCC model: a combination of glybican-3 with other routine parameters improves the diagnostic efficacy in hepatocellular carcinoma, Tumor Biol, vol.37, issue.9, pp.12571-12577, 2016.

S. Majeed, S. Mushtaq, M. Azam, and N. Akhtar,

M. Hussain and A. Loya, Diagnostic accuracy of glypican-3 in differentiating hepatocellular carcinoma from metastatic liver tumours, J Pak Med Assoc, vol.68, issue.7, pp.1029-1031, 2018.

R. Liang, Z. Liu, X. Piao, M. Zuo, J. Zhang et al., Research progress on GP73 in malignant tumors, Onco Targets Ther, vol.11, pp.7417-7421, 2018.

M. M. Ismail, H. K. Morsi, and N. A. Abdulateef,

M. K. Noaman, A. El-ella, and G. A. , Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance, Scand J Clin Lab Invest, vol.77, issue.3, pp.175-183, 2017.

R. M. Farag, A. Ayobi, D. Alsaleh, K. A. Kwon, H. J. El-ansary et al., Studying the impact of Golgi protein 73 serving as a candidate biomarker in early diagnosis for hepatocellular carcinoma among Saudi patients, Asian Pac J Cancer Prev, vol.20, issue.1, pp.12069-12074, 2014.

M. Guarino, D. Costanzo, G. G. Gallotta, and A. ,

R. Tortora, L. Paneghetti, F. Auriemma, C. Tuccillo, G. Fassina et al., Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in hepatocellular carcinoma patients, Scand J Clin Lab Invest, vol.77, issue.6, pp.448-453, 2017.

S. N. Thung, L. Giacomelli, A. Sergio, F. Farinati, U. Cillo et al., Squamous cell carcinoma antigen in human liver carcinogenesis, J Clin Pathol, vol.61, issue.4, pp.445-447, 2008.

S. L. Anwar, M. Lehmann-u-;-cabiati, M. Gaggini, M. M. Cesare, and C. Caselli, MicroRNAs: emerging novel clinical biomarkers for hepatocellular carcinomas, J Clin Med, vol.4, issue.8, pp.1631-1650, 2015.

D. Simone, P. Filipponi, F. Basta, G. Gastaldelli, A. Del-ry et al., Osteopontin in hepatocellular carcinoma: a possible biomarker for diagnosis and follow-up, Cytokine, vol.99, pp.59-65, 2017.

C. Hao, Y. Cui, S. Owen, W. Li, S. Cheng et al., Human osteopontin: potential clinical applications in cancer (review), Int J Mol Med, vol.39, issue.6, pp.1327-1337, 2017.

A. P. Soo, S. Eguchi, J. Gu, R. Ma-d-;-bruha, M. Jachymova et al., The role of osteopontin in the progression of solid organ tumour, Cell Death Dis, vol.9, issue.3, p.356, 2018.

M. Lenicek, P. Urbanek, T. Svestka, and L. Vitek, Osteopontin: a non-invasive parameter of portal hypertension and prognostic marker of cirrhosis, World J Gastroenterol, vol.22, issue.12, pp.3441-3450, 2016.

D. A. Moustafa, Possible role of microRNA-122 in modulating multidrug resistance of hepatocellular carcinoma, Indian J Clin Biochem, vol.15, issue.9, pp.21-30, 2015.

N. A. Lokman, M. P. Ween, M. K. Oehler, and C. Ricciardelli, The role of annexin A2 in tumorigenesis and cancer progression, Cancer Microenviron, vol.4, issue.2, pp.199-208, 2011.

R. J. Tressler, T. V. Updyke, T. Yeatman, and G. L. Nicolson, Extracellular annexin II is associated with divalent cationdependent tumor cell-endothelial cell adhesion of metastatic RAW117 large-cell lymphoma cells, J Cell Biochem, 1993.

V. M. Díaz, M. Hurtado, T. M. Thomson, J. Reventós, and R. Paciucci, Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro, Gut, vol.53, issue.3, pp.993-1000, 2004.

M. R. Sharma, L. Koltowski, R. T. Ownbey, G. P. Tuszynski, and M. Sharma, Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression, Exp Mol Pathol, vol.81, issue.2, pp.146-156, 2006.

Y. Shiozawa, A. M. Havens, Y. Jung, A. M. Ziegler, E. A. Pedersen et al., Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer, J Cell Biochem, vol.105, issue.2, pp.370-380, 2008.

M. E. Lozada, R. Chaiteerakij, and L. R. Roberts, Screening for hepatocellular carcinoma and cholangiocarcinoma: can biomarkers replace imaging?, Curr Hepatol Rep, vol.14, issue.2, pp.128-138, 2015.

J. Li, W. Gong, X. Li, R. Wan, F. Mo et al.,

P. Huang, Z. Hu, Z. Lai, X. Lu, and Y. Zhao, Recent progress of Wnt pathway inhibitor dickkopf-1 in liver cancer, J Nanosci Nanotechnol, vol.18, issue.8, pp.5192-5206, 2018.

Y. Zhou, W. Li, Y. Tseng, J. Zhang, and J. Liu, Developing slow-off dickkopf-1 aptamers for early-diagnosis of REVIEWS hepatocellular carcinoma, Talanta, vol.194, pp.422-429, 2019.

D. J. Pinato, F. A. Mauri, T. Lloyd, V. Vaira, C. Casadio et al., The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma, Br J Cancer, vol.108, issue.3, pp.621-628, 2013.

H. Axelrod, K. J. Pienta, L. A. Byers, L. Diao, J. Wang et al., Axl as a mediator of cellular growth and survival, Oncotarget, vol.5, pp.8818-8852, 2014.

L. Girard, M. Peyton, L. Shen, Y. Fan, U. Giri et al., An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance, Clin Cancer Res, vol.19, issue.1, pp.279-290, 2013.

T. M. D&apos;alfonso, J. Hannah, Z. Chen, Y. Liu, P. Zhou et al., Axl receptor tyrosine kinase expression in breast cancer, J Clin Pathol, vol.67, issue.8, pp.690-696, 2014.

P. D. Dunne, D. G. Mcart, J. K. Blayney, and M. Kalimutho,

S. Greer, T. Wang, S. Srivastava, C. W. Ong, K. Arthur et al., Van Schaeybroeck S. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer, Clin Cancer Res, vol.20, issue.1, pp.164-175, 2014.

J. D. Paccez, M. Vogelsang, M. I. Parker, L. F. Zerbini, H. Hodeib et al., Diagnostic and prognostic value of talin-1 and midkine as tumor markers in hepatocellular carcinoma in Egyptian patients, Asian Pac J Cancer Prev, vol.134, issue.5, pp.1503-1508, 2014.

K. Lindner, J. Gregán, S. Montgomery, and S. E. Kearsey, Essential role of MCM proteins in premeiotic DNA replication

, Mol Biol Cell, vol.13, issue.2, pp.435-444, 2002.

M. Liu, Q. Hu, M. Tu, X. Wang, Z. Yang et al., MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence, J Exp Clin Cancer Res, vol.37, issue.1, p.10, 2018.

Z. Liu, J. Li, J. Chen, Q. Shan, H. Dai et al., MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression, BMC Cancer, vol.18, issue.1, 0200.

T. C. Laurent, E. C. Moore, and P. Reichard, Enzymatic synthesis of deoxyribonucleotides. IV. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia Coli B, 147. Mollbrink A., Jawad R, vol.239, pp.3436-3444, 1964.

P. Edenvik, B. Isaksson, O. Danielsson, P. Stål, and A. P. Fernandes, Expression of thioredoxins and glutaredoxins in human hepatocellular carcinoma: correlation to cell proliferation, tumor size and metabolic syndrome, Int J Immunopathol Pharmacol, vol.27, issue.2, pp.169-183, 2014.

A. Gunes, E. Bagirsakci, E. Iscan, and G. Cakan-akdogan,

U. Aykutlu, S. Senturk, G. Ozhan, E. Erdal, D. Nart et al., Thioredoxin interacting protein promotes invasion in hepatocellular carcinoma, Oncotarget, vol.9, issue.96, pp.36849-36866, 2018.

H. S. Eun, B. S. Lee, R. Fox, S. Berhane, M. Teng et al., Clinical significance of the thioredoxin system and thioredoxin-domain-containing protein family in hepatocellular carcinoma, Dig Dis Sci, vol.64, issue.1, pp.2090-2098, 2014.

P. J. Johnson, S. J. Pirrie, T. F. Cox, S. Berhane, M. Teng et al., The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers, Cancer Epidemiol Biomarkers Prev, vol.23, issue.1, pp.144-153, 2014.

S. Berhane, H. Toyoda, T. Tada, and T. Kumada,

C. Kagebayashi, S. Satomura, N. Schweitzer, A. Vogel, M. P. Manns et al., Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients, Clin Gastroenterol Hepatol, vol.14, issue.6, pp.875-886, 2016.

S. Kotha, S. Neong, and K. Patel, Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma, Expert Rev Mol Diagn, vol.18, issue.8, pp.713-722, 2018.